Initial experiences with proton MR spectroscopy in treatment monitoring of mitochondrial encephalopathy by 源�吏꾩븘 et al.
Yonsei Med J   http://www.eymj.org    Volume 51   Number 5   September 2010672
Mitochondrial encephalopathy (ME) is a heterogeneous group of clinical synd-
romes associated with mitochondrial energy metabolism abnormalities. Presen-
tation is nonspecific with encephalomyopathy, failure to thrive, seizures, ophthal-
moplegia, and sensorineural hearing loss.1,2 Impaired energy production results
from overall dysfunction of the mitochondrial respiratory chain, which is compos-
ed of five enzymatic complexes embedded in the inner mitochondrial membrane.
There is no specific treatment for ME, and only conservative care is available.
One treatment is ketogenic diet therapy with a mitochondrial disease treatment
cocktail of coenzyme Q10, riboflavin, L-carnitine, and high-dose multivitamins;
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Purpose: Mitochondrial encephalopathy (ME) is a rare disorder of energy
metabolism. The disease course can roughly be evaluated by clinical findings. The
purpose of this study was to evaluate metabolic spectral changes using proton MR
spectroscopy (MRS), and to establish a way to monitor ME by neuroimaging.
Materials and Methods: Proton MRS data were retrospectively reviewed in 12
patients with muscle biopsy-confirmed ME (M : F = 7 : 5, Mean age = 4.8 years).
All received 1H-MRS initially and also after a ketogenic diet and mitochondrial
disease treatment cocktail (follow up average was 10.2 months). Changes of N-
acetylaspartate/creatine (NAA/Cr) ratio, choline/creatine (Cho/Cr) ratio, and lactate
peak in basal ganglia at 1.2 ppm were evaluated before and after treatment. Findings
on conventional T2 weighted MR images were also evaluated. Results: On
conventional MRI, increased basal ganglia T2 signal intensity was the most
common finding with ME (n = 9, 75%), followed by diffuse cerebral atrophy (n = 8,
67%), T2 hyperintense lesions at pons and midbrain (n = 4, 33%), and brain atrophy
(n = 2, 17%).  Lactate peak was found in 4 patients; 2 had disappearance of the peak
on follow up MRS. Quantitative analysis showed relative decrease of Cho/Cr ratio
on follow up MRS (p = 0.0058, paired t-test, two-tailed). There was no significant
change in NAA/Cr ratio. Conclusion: MRS is a useful tool for monitoring disease
progression or impro-vement in ME, and decrease or disappearance of lactate peak
and reduction of Cho/Cr fraction were correlated well with improvement of clinical
symptoms.
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INTRODUCTION
some favorable results have been reported.3,4
Diagnosis and monitoring can be achieved by clinical
findings and imaging techniques such as CT, conventional
MR imaging, and diffusion weighted MRI.5-7 MR spectro-
scopy (MRS) is a useful tool in evaluation of brain tissue
metabolites; applications in mitochondrial encephalopathy
are well documented.8-13 However, previous studies have
been limited to a single MRS study; there are no reports on
serial metabolite distribution changes during treatment.
The purpose of this study is to evaluate changes in the
metabolic spectrum by MRS spectroscopy, and to establish
a way to monitor disease course by neuroimaging.
The institutional review board approved retrospective
analysis of MRS data from patients with mitochondrial
encephalopathy. From July 2005 to October 2007, there
were 46 patients with muscle biopsy-confirmed mito-
chondrial disease. Twelve received 1H-MRS (M : F = 7 : 5,
Mean age = 4.8 years, range from 1 to 17 years) initially and
also after ketogenic diet and mitochondrial disease treat-
ment cocktail administration. The average interval be-
tween MRS scans was 10.2 months (range 5 to 17 months).
Data were retrospectively reviewed.
Localized 1H-MRS was performed on a 3.0T MRI
system (Achieva, Philips Medical Systems, Best, Nether-
lands) using an 8-channel SENSE head coil. Two water-
suppressed 1H-MR spectra were obtained from a voxel
located in the basal ganglia (voxel, 2 × 2 × 2 mL). The
following spectral acquisition parameters were used with
the point resolved spectroscopy sequence (PRESS) me-
thod: Spectra BW = 2,000 Hz, TR = 2.0 s, TE = 288/144
ms, acquisition number = 128. All raw data were process-
ed using the SpectroView software package (Philips
Medical System, Best, Netherlands), with Gaussian line
broadening of 3Hz, zero, and linear phase correction.
Peaks were identified with known chemical shifts: lactate
at 1.2 ppm, N-acetylaspartate at 2.02 ppm, phosphocrea-
tinine and creatinine at 3.05 ppm, and choline-containing
compounds at 3.22 ppm. Pre- and post-treatment MR
spectra were evaluated for change in choline/creatinine
(Cho/Cr) and N-acetylasparte/creatinine (NAA/Cr) ratios.
Presence of a lactate doublet peak was also monitored at
1.2 ppm, and confirmed by showing inversion on half TE
sequence (TE = 144 ms) [(-): absence of lactate doublet,
(+): faint presence of lactate doublet, (++): definite pre-
sence of lactate doublet]. Morphological findings on con-
ventional T2 weighted images were also assessed, with
emphasis on abnormal signals in the basal ganglia, brain
stem, and any atrophic changes in brain parenchyma.
Six, five, and one patient were diagnosed with mitochond-
rial respiratory chain (MRC) I, MRC IV, and MRC II
deficiency, respectively (Table 1). Clinically, 2 (patients
No. 2 and 11) had Leigh disease and 1 (patient No. 8) had
Kearn-Sayre Syndrome. The other 9 had uncategorized
MRC encephalopathies. All had mild to moderate clinical
improvement between pre- and post-treatment MRS studies,
such as decreased seizure frequency, improved general
condition, and improved developmental status.
On conventional T2 weighted images (T2WI), all had
abnormal findings. Increased basal ganglia T2 signal
intensity was the most common finding with ME (n = 9,
75%), followed by diffuse cerebral atrophy (n = 8, 67%).
Four (33%) patients had increased midbrain and pons
signal lesions. Cerebellar atrophy (17%) was found in 2
patients, along with diffuse cerebral atrophy (Table 1). Lac-
tate peak was found in 4 patients; 2 had disappearance of
the peak on follow up scan.  One patient showed marked
reduction of lactate peak after ketogenic diet and mitocho-
ndrial cocktail therapy (Case #2, Fig. 1), but the other pa-
tient showed no remarkable change of lactate peak before
and after treatment.
Quantitative analysis showed relative decrease of Cho/Cr
ratio on follow up MRS (p = 0.0058, paired t-test, two-
tailed). There was no significant change in NAA/Cr ratio.
However, all three patients with normal basal ganglia
signal on T2WI showed elevated NAA/Cr ratio after keto-
genic diet. On anatomical imaging, there were no remar-
kable changes of brain atrophy or newly developed T2
hyperintense lesions.
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Fig. 1. Two-year-old male with Leigh disease (case 2). Pre-treatment MRS
shows high lactate peak (arrow) at basal ganglia. One year follow up MRS
shows decrease of lactate (double arrows) and restoration of NAA. NAA, N-
acetylaspartate.
Mitochondrial respiratory chain disease or encephalopathy
is a rare disorder of energy metabolism. Clinical charac-
teristics and prognosis are still under investigation. With
the development of electron microscopic diagnosis and
enzyme assay technique, many children with previous
uncertain etiologies have been diagnosed with ME.  Typi-
cal imaging findings are non-specific cortical T2 hyper-
intensities, progressive atrophy, and encephalitis, similar to
findings without evidence of infectious etiologies.
Using brain MR examinations, we investigated 12 pati-
ents with established ME, and found a wide range of
structural and metabolic abnormalities. Our results are in
agreement with previous studies which support the role of
MRS as a confirmatory test.1,11,12,14,15 Our study also supports
the use of MRS for monitoring ME treatment by measur-
ing the Cho/Cr ratio and lactate peak. As clinical symptoms
and neurologic function improve, the Cho/Cr ratio and
lactate amplitude decrease.
As MRS can detect biochemical metabolites concen-
tration in vivo, it is more sensitive than MR imaging in
assessment of brain tissue metabolite alterations, such as
increased lactate fraction. In our study, all patients had
various T2WI MR findings which did not change during
treatment, while differences in metabolite fraction were
seen on serial MRS.
Although there are doubts about ketogenic diet effi-
ciency,16 recent studies present remarkable successes.
Prasad, et al.17 showed that in intractable epilepsy treated
with ketogenic diet, nearly one third became seizure-free,
another third had significantly reduced seizure frequency,
and the remainder did not benefit significantly. Our pati-
ents had no remarkable complications with conservative
treatment.  Instead, seizure frequency was decreased and
neurologic function improved. These clinical findings
were correlated well with MRS changes.
This study has some limitations. First, there are no age
matched controls for pediatric MRS data. We could only
compare two consecutive studies with longitudinal analy-
sis. Previous MRS studies of healthy children have revealed
that basal ganglia NAA increases until adolescence.18
Therefore, NAA increase during ME disease course cannot
be explained by treatment effects. Also, Gupta, et al.19
showed that adequate treatment for hypoparathyroidism
induced gradual Cho/Cr reduction, similar to our study. As
choline decreases according to myelination and matu-
ration, Cho/Cr reduction is not affected solely by a keto-
genic diet. However, lactate peak is definitely abnormal in
disease conditions, such as ME, therefore, reduction or
resolution is a good indicator for disease monitoring or
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DISCUSSION
treatment assessment.
Second, this study is a retrospective review of MRS data
in a large patient pool, therefore, follow up periods are
quite variable. Ideal and future study design should include
pre- and post-treatment serum and CSF lactate level check,
uniform follow up periods and more homogenous patient
group selection. Definition of mitochondrial encephalo-
pathy is still under investigation, therefore, we included
wide variety of diseases, however, future application should
be focused on more specific disease group. Third, as there
is no specific treatment for ME, multiple therapies, such as
antiepileptics, ketogenic diets, and mitochondrial disease
cocktails, were used. It is, therefore, difficult to identify treat-
ments responsible for clinical improvement and MRS
changes. 
In short, this is a primitive and pilot study of MR spec-
troscopy uses in mitochondrial disease. Diverse patient
characteristics and follow up periods are basic limitations
of this study. Furthermore, obtaining normal controls for
MR spectroscopy is necessary. Data from normal children
and sham control are basically impossible due to disease
nature and ethical problems. However, this study has
clarified some of the diverse findings of ME on routine
MRI & MR spectroscopy; these results can provide beni-
fits to future research.
In conclusion, we found that MRS is a useful tool for
monitoring disease progression or improvement in ME.
Despite lack of change on T2 weighted images, MRS
depicted metabolite changes during ketogenic diet and
mitochondrial cocktail therapy. Decreased lactate peak and
Cho/Cr fraction were correlated well with improvement of
clinical symptoms.
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